Background: Clinical diagnosis of Alzheimer disease (AD) is challenging, with a 70.9%-87.3% sensitivity and 44.3%-70.8% specificity, compared with autopsy diagnosis. Florbetapir F18 positron emission tomography (FBP-PET) estimates beta-amyloid plaque density antemortem. Methods: Of 2052 patients (Z55 years old) clinically diagnosed with mild or moderate AD dementia from 2 solanezumab clinical trials, 390 opted to participate in a FBP-PET study addendum. We analyzed baseline prerandomization characteristics.
INTRODUCTION
Accurate diagnosis of the causes of cognitive impairment allows physicians, patients, and patients' families to manage treatments for the underlying disorder(s) and develop a more focused plan for future psychosocial and medical needs. [1] [2] [3] [4] Additionally, patients appreciate receiving the diagnosis. 5 Among the top 4 causes for dementia, Alzheimer disease (AD) is the most common followed by vascular, Lewy body, and frontotemporal dementias. 6 The clinical diagnosis of AD is challenging and often not made in a timely fashion, especially by primary care physicians who may wait for several years to make and communicate the diagnosis to those affected and their family members, in part, due to uncertainty. [7] [8] [9] Care must be taken to include a thorough assessment of signs and symptoms, as well as central nervous system and medical conditions known to cause or mimic dementia. Blood tests and structural (head computerized tomography (CT) or magnetic resonance imaging (MRI)) and functional positron emission tomography (PET) neuroimaging using fluorodeoxyglucose (FDG)-PET are commonly used during differential diagnosis, along with neuropsychologic testing. Cerebrospinal fluid (CSF) measurement of soluble AD biomarkers for soluble amyloid-beta (β) and tau is clinically available, but results are not widely standardized and patient acceptance of lumbar puncture varies. Newer PET technology that detects β-amyloid plaque in the living brain is more recently increasing in availability and use. Tau PET is under development
and not yet ready for use in clinical practice. β-Amyloid neuropathologic changes characteristic of AD occur decades before the first clinical symptoms appear. 10, 11 A number of medications currently in development for potential disease modification target the amyloid cascade. In addition, the field is moving toward making and communicating an accurate diagnosis of AD earlier, as it may decrease medical costs, 12 help families understand the need for intervention and support, and increase the likelihood for patient involvement in future decisions about, for example, their health care, finances, and other life plans. 13 Clinically, the diagnosis of AD dementia is made by assessing cognitive, language, and functional abilities using the International Classification of Diseases, tenth revision (ICD-10), Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV), and National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS/ ADRDA) criteria.
14 However, a definitive diagnosis of AD is made only by neuropathologic examination, at autopsy or rarely with brain biopsy. When data from the National Alzheimer Coordinating Center were analyzed to determine accuracy of a clinical diagnosis for possible or probable AD dementia vs neuropathologic findings characteristic of AD at autopsy, sensitivity ranged from 70.9%-87.3% and specificity ranged from 44.3%-70.8%, depending on the levels of clinical and neuropathologic criteria used. 15 In 82 elderly patients in the OPTIMA study, the agreement between clinical and final cliniconeuropathologic diagnosis using the Consortium to Establish a Registry for Alzheimer Disease was substantial (κ ¼ 0.7), when possible and probable AD categories were combined. 16 Because knowledge about the clinical manifestations and biology of AD has increased considerably, the long-standing NINCDS/ADRDA criteria for AD were revised in 2011. Changes were made in the clinical criteria for diagnosis, and biomarker evidence was integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. 17 Suggested biomarkers include those from 2 categories: β-amyloid related including CSF Aβ-1-42 levels and amyloid PET neuroimaging, and neurodegeneration including CSF-tau and phospho-tau levels, FDG-PET, MRI. The apolipoprotein E ε4 genotype (APOE4) is the most robust genetic risk factor for sporadic late-onset AD, but it is not an absolute predictor even in patients with APOE4 homozygote status who are at very high risk to develop AD. 18 A total of 3 PET radiotracers for β-amyloid plaque detection are currently approved by the Food and Drug Administration, including florbetapir F18 (FBP) PET, as a diagnostic tool for patients with cognitive impairment suspected of having AD. 19, 20 FBP-PET visual interpretation and quantitative estimates of cortical amyloid plaques correlated with the presence and quantity of β-amyloid pathology at autopsy, respectively. 19 FBP can be used to distinguish individuals with sparse to no amyloid plaques from those with moderate to frequent amyloid plaques using a visual binary interpretation of the PET scan. 21 The FBP-PET positive or negative scans have also been defined in research using a cutoff on the standardized uptake value ratio (SUVR), a quantitative analysis of the ratio of cortical to cerebellar signal. 21, 22 We report a post hoc analysis of patients with a clinical diagnosis of mild or moderate probable AD dementia by dementia experts who participated in biomarker substudies in 2 registration clinical trials of solanezumab. We investigated whether prerandomization clinical characteristics, cognitive, neuropsychiatric, or functional scores differed between patients with or without clinically significant β-amyloid plaque deposition as measured with FBP-PET. The purpose was to ascertain whether any clinically available characteristics could have reliably distinguished the amyloid status of patients.
MATERIAL AND METHODS

Patients and Design
Study data are for a subset of patients (n ¼ 390) among 2052 patients from 2 nearly identical solanezumab registration trials 23 pooled for this cross-sectional, post hoc analysis. Patients in this report were Z55 years, clinically diagnosed with mild or moderate AD dementia and opted to participate in an FBP-PET scan study addendum at sites with PET imaging centers. Demographic, cognitive, neuropsychiatric, genetic, and FBP-PET images were obtained at baseline before randomization to drug. Amyloid positivity was not a study entry criterion. Both trials had identical entry criteria and enrolled medically stable male and female patients with probable AD per NINCDS/ADRDA criteria. 24 Inclusion criteria were the following: Modified Hachinski Ischemia Scale r4, Geriatric Depression Scale (GDS) short form r6, and Mini-Mental State Examination (MMSE) between 16 and 26 inclusive. Other inclusion criteria were MRI or CT scan performed within the previous 2 years with no findings inconsistent with a diagnosis of AD. Patients were permitted to be on concurrent medications for AD if they had been on the medication for at least 4 months and at a stable dose for at least 2 months before study randomization. About 89% of patients were taking cholinesterase inhibitors (such as donepezil, galantamine, rivastigmine, or tacrine) with or without memantine at the time of study entry. Our trial designs defined mild AD dementia as MMSE scores of 20-26 (inclusive) and moderate as MMSE 16-19. 23 All patients and caregivers provided written informed consent according to the Declaration of Helsinki, and the study procedures were approved by the institutional review boards. A complete description of the primary studies can be found in Doody et al. 23 
Neuropsychiatric and Functional Assessment
Various assessment tools including measures of cognition, global functioning, and psychopathology were administered at baseline. The Alzheimer Disease Assessment Scale-Cognitive Subscale, 14-item version (ADAS-Cog14) 25 31 The GDS 32 is a 15-item measure for depressive symptoms with scores ranging from 0-15 (more symptoms), in which a 7-point cutoff indicates syndromal depression.
FBP-PET Neuroimaging
At baseline before drug randomization, PET neuroimaging was performed after the intravenous administration of 370 MBq of F18-FBP. Images were obtained and emission data were collected, corrected for attenuation, and reconstructed using the 3-dimensional maximum a priori method specified in the studies' protocols. 23 The SUVR was calculated as the ratio of the mean of 6 cortical regions of interest (frontal, temporal, precuneus, parietal, anterior cingulate, and posterior cingulate), relative to the whole cerebellum reference region with a threshold for amyloid positivity of 41.10.
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Laboratory Analyses APOE4 genotype was determined as a part of the serum biochemical measurements and hematologic analyses used in the original trials to analyze for effects of APOE4 carrier status.
Statistical Analyses
All statistical analyses were performed using SAS 9.2 (Cary,
RESULTS
Demographic Characteristics
Of 390 mild and moderate probable AD dementia patients, 87 (22.4%) were found to be FBP-PET negative (Table) . The negative scan group had a significantly lower proportion of females (43.7% vs 56.3%; p ¼ 0.0145) than the positive scan group. Baseline age and education were similar between the scan groups, though disease duration since onset of symptoms was significantly longer in the positive group (p ¼ 0.0056).
Positive FBP-PET scans occurred in 72.5% of the mild vs 86.9% of the moderate AD dementia group (p ¼ 0.0014). In the mild group, those with negative scans were significantly younger than those with positive (p ¼ 0.0051).
Clinical Characteristics
There was less severe cognitive impairment in the negative compared with positive scan group as indicated by mean ADAS-Cog14 (28. MMSE scores were significantly different between scan groups only in the mild dementia group (p ¼ 0.0005). Among the MMSE domains, orientation and recall were significantly worse in the amyloid-positive group (p o 0.0001 and p ¼ 0.0003), again driven by the mild dementia group. Similar to MMSE, the only difference for ADAS-Cog14 was in the mild dementia group where those with negative scans had significantly better scores than those with positive scans (p o 0.0001).
More years of education (r ¼ 0.1835; p ¼ 0.0003), but not age (r ¼ 0.0388; p ¼ 0.4449), correlated significantly with higher FBP-PET SUVR indicating amyloid burden.
A significantly smaller proportion of the negative scan group was APOE4 carriers (22.62% vs 62.85%; p o 0.001). Homozygotes for the APOE4 allele were highly likely to be amyloid positive (mild ¼ 100.00%, moderate ¼ 95.83%).
No differences were found between positive and negative scan groups or their mild AD subgroups on ADCS-ADL, CDR-SB, NPI, or GDS.
DISCUSSION
We retrospectively analyzed pooled clinical and FBP-PET scan data from baseline visits for 390 clinical trial patients who had been clinically diagnosed as having mild or moderate probable AD dementia. About onefifth (22.4%) of patients did not have evidence of β-amyloid plaque pathology despite having received a clinical diagnosis of AD by expert physicians participating in therapeutic clinical trials. Considering only the mild dementia cases, 27.5% had negative FBP-PET scans, consistent with the literature that earlier phases of AD are more difficult to diagnose accurately. Though clinically evaluated before enrollment to rule out other causes for their cognitive impairment (e.g., vascular dementia, Parkinson's disease, major depression), these patients who are amyloid-negative presented with the AD clinical phenotype yet lacked sufficient β-amyloid plaque density on FBP-PET scans to support their AD diagnosis. The cause of their dementia is not known as part of this research but possibilities include tauopathies, frontotemporal dementia, and hippocampal sclerosis.
It is possible to have false-positive or false-negative PET scan results, though the pivotal FBP-PET registration trials showed very high concordance with AD neuropathologic autopsy diagnoses, including 96% sensitivity and 100% specificity in those whose scans were performed within the year before autopsy.
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Patients who are amyloid-negative with probable AD have been reported in other AD clinical trials where amyloid biomarkers have been used. In the IDENTITY phase 3 study program using semagacestat and similar entry criteria, 18% of patients with clinically diagnosed probable mild or moderate AD dementia who had an FBP-PET scan were amyloidnegative, where 24% of the mild dementia cases were negative. 33 In bapineuzumab clinical trials, negativeamyloid PET scans (using C11-Pittsburgh Compound-B (PiB)) were found in 22.4% of placebo completers in phase 3 clinical registration trials and 16% in phase 1b clinical trials. [34] [35] [36] Similar to Witte et al., 33 we did not find any clinical characteristic that could reliably predict amyloid status even though some had statistically significant differences-such as disease duration. Neuropsychiatric symptoms, including depression, mood, agitation or aggression, and frontal symptoms, did not differ between any of the groups. In the mild group, the patients who are amyloid-negative were less cognitively impaired and somewhat younger (early 70s) than the amyloid positive, without functional differences. MMSE domains for recall and orientation were significantly less impaired in the amyloidnegative mild group. Interestingly, in the moderate group, functional impairment was greater in negative than positive patients for both basic and instrumental ADLs. Though these differences are interesting, they do not form a pattern that could on its own elucidate the underlying cause for negative-amyloid cases. Antemortem tests may not exist yet for some of the causes to be considered. APOE4 genotype is a wellknown risk factor for AD and amyloid deposition, though these are not synonymous. 37, 38 Chiao et al. 35 found that 23% of APOE4 carriers were amyloidnegative compared with 57% of noncarriers. Salloway et al. 36 reported that a greater number of APOE4 noncarriers were PiB-PET negative (36.1%) compared with APOE4 carriers (6.5%). Witte et al. 33 also
reported that negative FBP-PET scans were more common in APOE4 noncarriers (82%) than carriers (18%). Similarly, we found fewer APOE4 carriers in the FBP-PET negative vs the positive group (22.62% vs 62.85%), and homozygotes for the APOE4 allele were highly likely to be FBP-PET positive (97.92%). In a clinically diagnosed patient, APOE4 homozygosity could be potentially useful in place of amyloid PET. Patients in the study were diagnosed clinically with AD using robust inclusion and exclusion criteria.
Although not all patients had amyloid PET scans, among those who did, a positive scan in combination with the clinical diagnosis should result in a high likelihood of AD.
One limitation of our report is that only a subset (390 of 2052) patients from 2 large registration trials were represented in this analysis, which may not be generalizable to the community population. However, these data do replicate prior findings by others in which up to 18.0% of patients 33 diagnosed with AD by dementia specialists did not have supportive evidence on amyloid PET. 39 The 2 characteristic neuropathologic findings of AD are β-amyloid plaques and neurofibrillary tangles, which are aggregates of abnormal forms of tau. Although recent developments in tau PET imaging have made it possible to visualize tau accumulation in parts of the brain characteristic for AD, this technology is still under development and was not available in our studies. In this study, CSF levels of tau were not considered because they were only measured in a subset of patients 23 and not in all of the patients in the amyloid PET imaging group. Additionally, by the time of the dementia stage of AD, neurofibrillary tangle pathology is likely to be present along with β-amyloid plaque. Therefore, making use of tau imaging or measurement of CSF-tau is of little benefit to this particular study design.
Reliable differential clinical diagnosis in dementia would be helpful in communicating the course and prognosis to patients and families, identifying AD patients for clinical trials and in making appropriate treatment decisions.
14 Amyloid PET imaging is a validated and approved adjunctive biomarker in the diagnosis of AD. Our report and that of others form an emerging literature demonstrating that phenotype and a thorough but conventional dementia work-up cannot alone accurately diagnose AD antemortem, especially during earlier disease phases.
